Qiming-backed genomic testing firm Berry Oncology closes over $99m Series B1 round

Berry Oncology, a member company of China’s Berry Genomics, raised $99.15 million in a Series B1 round of financing to double down on developing genetic testing solutions for cancer screening.

China Merchants Capital, a joint venture (JV) between state-owned China Merchants Group and Asia’s warehouse operator GLP, led the new round, according to a statement on Wednesday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter